These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 23231456)

  • 41. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
    Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
    J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.
    Rink M; Lee DJ; Kent M; Xylinas E; Fritsche HM; Babjuk M; Brisuda A; Hansen J; Green DA; Aziz A; Cha EK; Novara G; Chun FK; Lotan Y; Bastian PJ; Tilki D; Gontero P; Pycha A; Baniel J; Mano R; Ficarra V; Trinh QD; Tagawa ST; Karakiewicz PI; Scherr DS; Sjoberg DD; Shariat SF;
    BJU Int; 2013 Mar; 111(3 Pt B):E30-6. PubMed ID: 22938654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer.
    Coen JJ; Paly JJ; Niemierko A; Kaufman DS; Heney NM; Spiegel DY; Efstathiou JA; Zietman AL; Shipley WU
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):311-6. PubMed ID: 23474117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients.
    van Onna IE; Oddens JR; Kok ET; van Moorselaar RJ; Bosch JL; Battermann JJ
    Eur Urol; 2009 Jul; 56(1):113-21. PubMed ID: 18722048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy.
    Hellenthal NJ; Ramirez ML; Evans CP; Devere White RW
    BJU Int; 2010 Feb; 105(4):485-8. PubMed ID: 19849694
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
    Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience.
    Perdonà S; Autorino R; Damiano R; De Sio M; Morrica B; Gallo L; Silvestro G; Farella A; De Placido S; Di Lorenzo G
    Cancer; 2008 Jan; 112(1):75-83. PubMed ID: 18008364
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.
    Cattrini C; Cerbone L; Rubagotti A; Zinoli L; Latocca MM; Messina C; Zanardi E; Boccardo F
    Clin Genitourin Cancer; 2019 Aug; 17(4):e724-e732. PubMed ID: 31160193
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder.
    Bex A; de Vries R; Pos F; Kerst M; Horenblas S
    World J Urol; 2009 Feb; 27(1):101-6. PubMed ID: 18607595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer.
    Tran E; Souhami L; Tanguay S; Rajan R
    Am J Clin Oncol; 2009 Aug; 32(4):333-7. PubMed ID: 19381080
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Primary small cell carcinoma of the bladder].
    Tiguert R; Ravery V; Gheiler EL; Grignon DJ; Gudziak MR; Wood DP; Pontes JE
    Prog Urol; 1999 Apr; 9(2):256-60. PubMed ID: 10370949
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Dhar NB; Jones JS; Reuther AM; Dreicer R; Campbell SC; Sanii K; Klein EA
    BJU Int; 2008 Apr; 101(8):969-72. PubMed ID: 18005201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival].
    Chauvet B; Félix-Faure C; Davin JL; Choquenet C; Alfonsi M; Reboul F
    Cancer Radiother; 1998 Apr; 2 Suppl 1():85s-91s. PubMed ID: 9749086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era.
    Takaoka E; Matsui Y; Inoue T; Miyazaki J; Nakashima M; Kimura T; Oikawa T; Kawai K; Yoshimura K; Habuchi T; Ogawa O; Nishiyama H
    Jpn J Clin Oncol; 2013 Apr; 43(4):404-9. PubMed ID: 23444116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
    J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.